The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis
Open accessAbstract
The therapeutic efficacy of angiotensin II receptor antagonist, losartan, was studied in patients with nonalcoholic steatohepatitis (NASH). Seven patients with both NASH and hypertension were treated with losartan (50 mg/d) for 48 weeks. Treatment with losartan resulted in a significant decrease in blood markers of hepatic fibrosis, plasma TGF-β1 and serum ferritin concentration concurrently with an improvement in serum aminotransferase levels. Histological assessment showed improvement of hepatic necroinflammation in five patients, reduction of hepatic fibrosis in four patients, and disappearance of iron deposition in two patients. No side effect of treatment was noted at any time during the study. In conclusion, the present data raise the possibility that an angiotensin II receptor antagonist may be therapeutically efficacious for NASH. (Hepatology 2004.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Ludwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Protection from obesity-induced insulin resistance in mice lacking TNF-α function
Uysal, K. T., Wiesbrock, S. M., Marino, M. W., & Hotamisligil, G. S. (1997) · Nature · doi:10.1038/39335 · Cited by 2,234
Nonalcoholic Steatohepatitis: Summary of An Aasld Single Topic Conference
Neuschwander-Tetri, B. A., & Caldwell, S. H. (2003) · Hepatology · doi:10.1053/jhep.2003.50193 · Cited by 2,154
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities
Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078
Association of nonalcoholic fatty liver disease with insulin resistance
Marchesini, G., Brizi, M., Morselli-Labate, A. M., Bianchi, G., Bugianesi, E., McCullough, A. J., Forlani, G., & Melchionda, N. (1999) · The American Journal of Medicine · doi:10.1016/s0002-9343(99)00271-5 · Cited by 1,568
Powell, E. E., Cooksley, G. W. E., Hanson, R., Searle, J., Halliday, J. W., & Powell, L. W. (1990) · Hepatology · doi:10.1002/hep.1840110114 · Cited by 1,473
Neuschwander-Tetri, B. A., Brunt, E. M., Wehmeier, K. R., Oliver, D., & Bacon, B. R. (2003) · Hepatology · doi:10.1002/hep.1840380427 · Cited by 751
A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis
Promrat, K., Lutchman, G., Uwaifo, G. I., Freedman, R. J., Soza, A., Heller, T., Doo, E., Ghany, M., Premkumar, A., Park, Y., et al. (2004) · Hepatology · doi:10.1002/hep.20012 · Cited by 726
George, D. K., Goldwurm, S., Macdonald, G. A., Cowley, L. L., Walker, N. I., Ward, P. J., Jazwinska, E. C., & Powell, L. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70482-2 · Cited by 659
Therapeutic effects of restricted diet and exercise in obese patients with fatty liver
Ueno, T., Sugawara, H., Sujaku, K., Hashimoto, O., Tsuji, R., Tamaki, S., Torimura, T., Inuzuka, S., Sata, M., & Tanikawa, K. (1997) · Journal of Hepatology · doi:10.1016/s0168-8278(97)80287-5 · Cited by 609
Cytokines and Nash: A Pilot Study of the Effects of Lifestyle Modification and Vitamin E
Kugelmas, M., Hill, D. B., Vivian, B., Marsano, L., & McClain, C. J. (2003) · Hepatology · doi:10.1053/jhep.2003.50316 · Cited by 504
Abdelmalek, M. (2001) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(01)02691-0 · Cited by 439
Hasegawa, T., Yoneda, M., Nakamura, K., Makino, I., & Terano, A. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.01083.x · Cited by 408
Self-citationYOSHIJI, H., KURIYAMA, S., YOSHII, J., IKENAKA, Y., NOGUCHI, R., NAKATANI, T., TSUJINOUE, H., & FUKUI, H. (2001) · Hepatology · doi:10.1053/jhep.20001.28231 · Cited by 397
Matsuoka, M., & Tsukamoto, H. (1990) · Hepatology · doi:10.1002/hep.1840110412 · Cited by 291
Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver
Washington, K., Wright, K., Shyr, Y., Hunter, E. B., Olson, S. J., & Raiford, D. S. (2000) · Human Pathology · doi:10.1053/hupa.2000.8440 · Cited by 121
Immunohistochemical detection of transforming growth factor-β1 in fibrotic liver diseases
Nagy, P., Schaff, Z., & Lapis, K. (1991) · Hepatology · doi:10.1002/hep.1840140211 · Cited by 107
Togashi, N., Ura, N., Higashiura, K., Murakami, H., & Shimamoto, K. (2000) · Journal of Hypertension · doi:10.1097/00004872-200018110-00011 · Cited by 101
Iron Overload Augments Angiotensin II–Induced Cardiac Fibrosis and Promotes Neointima Formation
Ishizaka, N., Saito, K., Mitani, H., Yamazaki, I., Sata, M., Usui, S.-I., Mori, I., Ohno, M., & Nagai, R. (2002) · Circulation · doi:10.1161/01.cir.0000031161.77536.02 · Cited by 65
Cited by
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024
The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019)
Umemura, S., Arima, H., Arima, S., Asayama, K., Dohi, Y., Hirooka, Y., Horio, T., Hoshide, S., Ikeda, S., Ishimitsu, T., et al. (2019) · Hypertension Research · doi:10.1038/s41440-019-0284-9 · Cited by 1,880
Nonalcoholic fatty liver disease
Adams, L. A. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.045232 · Cited by 1,610
on behalf of The Japanese Society of Hypertension Committee for Guidelines for the Management of Hypertension, Ogihara, T., Kikuchi, K., Matsuoka, H., Fujita, T., Higaki, J., Horiuchi, M., Imai, Y., Imaizumi, T., Ito, S., et al. (2014) · Hypertension Research · doi:10.1038/hr.2014.68 · Cited by 1,385
Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis
Diehl, A. M., & Day, C. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1503519 · Cited by 1,283
Metadata
- Authors
- Yokohama, S., Yoneda, M., Haneda, M., Okamoto, S., Okada, M., Aso, K., Hasegawa, T., Tokusashi, Y., Miyokawa, N., & Nakamura, K.
- Venue
- Hepatology
- Published
- 2004-11
- Volume
- 40
- Issue
- 5
- Pages
- 1222-1225
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2059307783
- Cited by
- 458
- References
- 21
- FWCI
- 19.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.